Drug Profile
Research programme: stroke therapeutics - Affibody
Latest Information Update: 28 Jul 2019
Price :
$50
*
At a glance
- Originator Affibody
- Class Cardiovascular therapies; Small molecules
- Mechanism of Action High mobility group protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Stroke
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for research development in Stroke in Sweden
- 31 Jul 2017 Early research is ongoing (Affibody pipeline, July 2017)